Among these, the glucagon-like peptide (GLP) analogs are seriously restricted in their usage due to being injectable, and SGLT-2 inhibitors offer more benefits in HF patients, better tolerability, and once‐daily oral administration [6]. This evidence concerns the gene SLC5A2 and hydrops fetalis.